The experience and effectiveness of the Nova Scotia Rh program, 1964-84

Area of Science:

• Obstetrics and Gynecology
• Neonatal Medicine
• Immunology

Background:

• Erythroblastosis fetalis, now known as hemolytic disease of the newborn, poses significant risks to Rh-negative mothers carrying Rh-positive fetuses.
• Intrauterine transfusions have been a critical intervention for affected fetuses.
• The development of Rh immune globulin (RhIG) has revolutionized prevention strategies.

Purpose of the Study:

• To evaluate the long-term effectiveness of a comprehensive program aimed at reducing erythroblastosis fetalis.
• To assess the impact of intrauterine transfusions and RhIG prophylaxis on fetal survival and alloimmunization rates.

Main Methods:

• Retrospective analysis of data from a 20-year program (1964-1984) in Nova Scotia.
• Tracking of intrauterine transfusions, fetal survival rates, and Rh(D) alloimmunization cases.
• Evaluation of postpartum and antepartum Rh immune globulin administration protocols.

Main Results:

• Intrauterine transfusion survival rates improved significantly over the program's duration (45.6% to 66.7%).
• Survival rates for fetuses over 26 weeks' gestation also showed marked improvement (51.5% to 73.7%).
• Rh(D) alloimmunization incidence decreased dramatically to 1.5 per 1000 births, significantly lower than the expected 10 per 1000.

Conclusions:

• The integrated program combining intrauterine transfusions and RhIG prophylaxis has been highly effective in reducing erythroblastosis fetalis.
• Both postpartum and antepartum RhIG administration contribute to preventing Rh(D) alloimmunization.
• The program demonstrates a successful public health initiative in managing Rh incompatibility.